-
1.发明授权公开(公告)号：US08932627B2
公开(公告)日：2015-01-13
申请号：US11662172
申请日：2005-09-11
IPC分类号： A61K9/127 , A61K31/573
CPC分类号： A61K9/127 , A61K9/1271 , A61K31/573
摘要： The present invention provides pharmaceutical compositions comprising a glucocorticoid or glucocorticoid derivative stably encapsulated in a liposome. The glucocorticoid or glucocorticoid derivative is selected from an amphipathic weak base glucocorticoid or glucocorticoid derivative having a pKa equal or below 11 and a logD at pH 7 in the range between −2.5 and 1.5; or an amphipathic weak acid GC or GC derivative having a pKa above 3.5 and a logD at pH 7 in the range between −2.5 and 1.5. The therapeutic effect of the pharmaceutical composition of the invention was exhibited in vivo with appropriate models of multiple sclerosis and cancer.
摘要翻译： 本发明提供包含稳定包封在脂质体中的糖皮质激素或糖皮质激素衍生物的药物组合物。 糖皮质激素或糖皮质激素衍生物选自pKa等于或低于11的两亲性弱碱性糖皮质激素或糖皮质激素衍生物，在pH7的logD在-2.5和1.5之间的范围内; 或pKa高于3.5的两亲性弱酸GC或GC衍生物，pH7的logD在-2.5和1.5之间的范围内。 用适当的多发性硬化症和癌症模型在体内展示本发明的药物组合物的治疗效果。
-
公开(公告)号：US07744920B2
公开(公告)日：2010-06-29
申请号：US11662174
申请日：2005-09-11
CPC分类号： A61K9/127 , A61K9/1271 , A61K31/573
摘要： The present invention provides the use of a glucocorticoid (GC) or of a GC derivative encapsulated in a liposome for the preparation of a pharmaceutical composition for the treatment of an inflammatory associated condition in a subject, provided that said condition is not associated with a neurodegenerative disease or disorder. A specific use concerns a liposomal formulation comprising methylprednisolone sodium hemisuccinate (MPS) for the treatment of rheumatoid arthritis.
摘要翻译： 本发明提供糖皮质激素（GC）或包封在脂质体中的GC衍生物用于制备用于治疗受试者的炎症相关病症的药物组合物的用途，条件是所述病症与神经变性不相关 疾病或病症。 具体用途涉及包含用于治疗类风湿性关节炎的甲泼尼龙钠半琥珀酸钠（MPS）的脂质体制剂。
-
3.发明申请公开(公告)号：US20080058294A1
公开(公告)日：2008-03-06
申请号：US11662172
申请日：2005-09-11
CPC分类号： A61K9/127 , A61K9/1271 , A61K31/573
摘要： The present invention provides pharmaceutical compositions comprising a glucocorticoid or glucocorticoid derivative stably encapsulated in a liposome. The glucocorticoid or glucocorticoid derivative is selected from an amphipathic weak base glucocorticoid or glucocorticoid derivative having a pKa equal or below 11 and a logD at pH 7 in the range between −2.5 and 1.5; or an amphipathic weak acid GC or GC derivative having a pKa above 3.5 and a logD at pH 7 in the range between −2.5 and 1.5. The therapeutic effect of the pharmaceutical composition of the invention was exhibited in vivo with appropriate models of multiple sclerosis and cancer.
摘要翻译： 本发明提供包含稳定包封在脂质体中的糖皮质激素或糖皮质激素衍生物的药物组合物。 糖皮质激素或糖皮质激素衍生物选自pKa等于或低于11的两亲性弱碱性糖皮质激素或糖皮质激素衍生物，在pH7的logD在-2.5和1.5之间的范围内; 或pKa高于3.5的两亲性弱酸GC或GC衍生物，pH7的logD在-2.5和1.5之间的范围内。 用适当的多发性硬化症和癌症模型在体内展示本发明的药物组合物的治疗效果。
-
公开(公告)号：US20080003276A1
公开(公告)日：2008-01-03
申请号：US11662174
申请日：2005-09-11
CPC分类号： A61K9/127 , A61K9/1271 , A61K31/573
摘要： The present invention provides the use of a glucocorticoid (GC) or of a GC derivative encapsulated in a liposome for the preparation of a pharmaceutical composition for the treatment of an inflammatory associated condition in a subject, provided that said condition is not associated with a neurodegenerative disease or disorder A specific use concerns a liposomal formulation comprising methylprednisolone sodium hemisuccinate (MPS) for the treatment of rheumatoid arthritis.
摘要翻译： 本发明提供糖皮质激素（GC）或包封在脂质体中的GC衍生物用于制备用于治疗受试者的炎症相关病症的药物组合物的用途，条件是所述病症与神经变性不相关 疾病或病症具体用途涉及包含用于治疗类风湿性关节炎的甲泼尼龙钠半琥珀酸钠（MPS）的脂质体制剂。
-
公开(公告)号：US20130243749A1
公开(公告)日：2013-09-19
申请号：US13700974
申请日：2011-06-02
申请人： Wayne A. Marasco , Jianhua Sui , Yuval Avnir
发明人： Wayne A. Marasco , Jianhua Sui , Yuval Avnir
IPC分类号： C07K16/42 , A61K39/395 , A61K39/145
CPC分类号： C07K16/4216 , A61K39/145 , A61K39/39 , A61K39/39566 , A61K2039/55516 , C07K16/1018 , C07K16/4241 , C07K2317/24 , C07K2317/35 , C07K2317/56 , C07K2317/567 , C07K2317/622 , C07K2317/76 , C07K2317/92
摘要： Disclosed is a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene VHI-69. The antibody is derived from Mab G6 and recognizes the same epitope. Moreover, the antibody is used in combination with vaccines to augment an immune response to the antigen.
摘要翻译： 公开了与人免疫球蛋白重链可变区种系基因VHI-69结合的人源化单克隆抗体。 该抗体衍生自Mab G6并识别相同的表位。 此外，抗体与疫苗组合使用以增加对抗原的免疫应答。
-
公开(公告)号：US09527924B2
公开(公告)日：2016-12-27
申请号：US13700974
申请日：2011-06-02
申请人： Wayne A. Marasco , Jianhua Sui , Yuval Avnir
发明人： Wayne A. Marasco , Jianhua Sui , Yuval Avnir
IPC分类号： C07K16/42 , A61K39/395 , A61K39/145 , C07K16/10 , A61K39/00 , A61K39/39
CPC分类号： C07K16/4216 , A61K39/145 , A61K39/39 , A61K39/39566 , A61K2039/55516 , C07K16/1018 , C07K16/4241 , C07K2317/24 , C07K2317/35 , C07K2317/56 , C07K2317/567 , C07K2317/622 , C07K2317/76 , C07K2317/92
摘要： Disclosed is a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene VHI-69. The antibody is derived from Mab G6 and recognizes the same epitope. Moreover, the antibody is used in combination with vaccines to augment an immune response to the antigen.
摘要翻译： 公开了与人免疫球蛋白重链可变区种系基因VHI-69结合的人源化单克隆抗体。 该抗体衍生自Mab G6并识别相同的表位。 此外，抗体与疫苗组合使用以增加对抗原的免疫应答。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.021 秒)
